IC
FBRX

Ikarian Capital’s Forte Biosciences FBRX Stock Holding History

Ikarian Capital’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Sell
20,972
-98,000
-82% -$2.32M 0.05% 123
2026
Q1 		$3.08M Sell
118,972
-181,028
-60% -$5.22M 0.25% 81
2025
Q4 		$8.18M Hold
300,000
– – 0.64% 45
2025
Q3 		$4.5M Sell
300,000
-176,443
-37% -$2.03M 0.45% 58
2025
Q2 		$6.16M Sell
476,443
-132,782
-22% -$1.14M 1.18% 30
2025
Q1 		$4.73M Hold
609,225
– – 0.58% 39
2024
Q4 		$13.8M Buy
+609,225
New +$7.25M 1.88% 10

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ikarian Capital's FBRX Position: Q2 2026 in Review

Ikarian Capital reduced its Forte Biosciences (FBRX) stake by 82% in Q2 2026, selling an estimated $2.32M and leaving 20,972 shares worth $446K. The position accounts for 0.05% of the portfolio, ranked #123.

Ikarian Capital first reported a position in FBRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.8M in Q4 2024. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Ikarian Capital held 20,972 shares of Forte Biosciences worth $446K as of Q2 2026.
  • Ikarian Capital sold 98,000 Forte Biosciences shares in Q2 2026, an estimated $2.32M.
  • Forte Biosciences made up 0.05% of Ikarian Capital's portfolio in Q2 2026, its #123 holding.
  • Ikarian Capital first reported a position in Forte Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Ikarian Capital's Forte Biosciences position peaked at $13.8M in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.